Articles publicats

Cerca col·leccions:

Ordena'ls per:	Mostrar els resultats:	Format de visualizació:

Articles publicats	1 registres trobats	La cerca s'ha fet en 0.01 segons.

10 p, 1.5 MB

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis : analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 / Cork, M.J. (University of Sheffield Medical School) ; Eckert, L. (Sanofi) ; Simpson, E.L. (Oregon Health & Science University) ; Armstrong, A. (Keck School of Medicine at USC. University of Southern California) ; Barbarot, Sebastien (CHU Hôtel-Dieu) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Girolomoni, G. (University of Verona) ; de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Wollenberg, A. (Klinikum der Universität München) ; Kataoka, Y. (Osaka Habikino Medical Center) ; Remitz, A. (Helsinki University Central Hospital) ; Beissert, Stefan (Technische Universität Dresden) ; Mastey, V. (Regeneron Pharmaceuticals Inc.) ; Ardeleanu, Marius (Regeneron Pharmaceuticals Inc.) ; Chen, Z. (Regeneron Pharmaceuticals Inc.) ; Gadkari, A. (Regeneron Pharmaceuticals Inc.) ; Chao, J. (Regeneron Pharmaceuticals Inc.) ; Universitat Autònoma de Barcelona
Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. [...]
2020 - DOI (Digital Object Identifier)

10.1080/09546634.2019.1612836
Journal of Dermatological Treatment, Vol. 31 Núm. 6 (17 2020) , p. 606-614

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.